← back to search

Robert F. Schwabe

Columbia University Irving Medical Center · US
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver physiology and pathology, Organ Transplantation Techniques and Outcomes, and Liver Diseases and Immunity.
h-index
83
citations
35,266
works
254
NIH funding
primary concept
Medicine
email

Recent publications

Hepatic stellate cells control liver zonation, size and functions via R-spondin 3
Nature 2025cited by 73position: lastdoi
Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease
Nature Reviews Gastroenterology & Hepatology 2025cited by 64position: firstdoi
Immunology and immunotherapy of cholangiocarcinoma
Nature Reviews Gastroenterology & Hepatology 2023cited by 174position: middledoi
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits
Journal of Hepatology 2022cited by 502position: middledoi
Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis
Nature 2022cited by 322position: lastdoi
Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome
Nature 2022cited by 235position: middledoi
The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver
Science Translational Medicine 2022cited by 94position: lastdoi
β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma
Gastroenterology 2022cited by 47position: middledoi
Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH)
Liver International 2022cited by 46position: middledoi
Enterohepatic Shunt-Driven Cholemia Predisposes to Liver Cancer
Gastroenterology 2022cited by 20position: middledoi
Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3
Hepatology Communications 2022cited by 12position: middledoi
A molecular single-cell lung atlas of lethal COVID-19
Nature 2021cited by 720position: middledoi
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations
Cancer Cell 2021cited by 399position: lastdoi
Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts
Journal of Clinical Investigation 2021cited by 350position: lastdoi
Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation
Journal of Hepatology 2021cited by 108position: middledoi
Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis
Cell Metabolism 2020cited by 198position: middledoi
Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features
Journal of Hepatology 2020cited by 64position: middledoi
c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis
Nature Metabolism 2020cited by 39position: middledoi
Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis
Cell Metabolism 2019cited by 247position: middledoi
Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis
Science Translational Medicine 2018cited by 242position: middledoi
NLR Family Pyrin Domain‐Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice
Hepatology 2018cited by 141position: middledoi
The nucleoprotein High-mobility group box 1 critically regulates the immune response to bacterial infection
Zeitschrift für Gastroenterologie 2018cited by 0position: middledoi
MicroRNA‐21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis
Hepatology 2017cited by 82position: lastdoi
Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis
Cell Metabolism 2016cited by 402position: middledoi
Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis
Cell stem cell 2016cited by 201position: middledoi
In Vivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis
Cell stem cell 2016cited by 141position: middledoi
Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis
Gut 2016cited by 39position: lastdoi
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
Nature 2015cited by 1,791position: middledoi
Gremlin 1 Identifies a Skeletal Stem Cell with Bone, Cartilage, and Reticular Stromal Potential
Cell 2015cited by 647position: middledoi
Hepatic inflammation and fibrosis: Functional links and key pathways
Hepatology 2014cited by 936position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Ira Tabas · Columbia University Irving Medical Center5 papers (2016–2022)Silvia Affò · Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer5 papers (2017–2022)Ingmar Mederacke · Medizinische Hochschule Hannover5 papers (2012–2022)Jorge Matías Caviglia · Brooklyn College4 papers (2012–2022)Xiaobo Wang · Dali University4 papers (2016–2020)Geum‐Youn Gwak · Kangbuk Samsung Hospital4 papers (2012–2017)Richard A. Friedman · Columbia University Irving Medical Center4 papers (2012–2017)Xin Chen · Qingdao University3 papers (2017–2022)Bishuang Cai · University of California, Los Angeles3 papers (2016–2020)Utpal B. Pajvani · Columbia University Irving Medical Center3 papers (2018–2020)Myoung Kuk Jang · Hallym University3 papers (2012–2017)Aveline Filliol · UMass Memorial Medical Center3 papers (2021–2022)Dianne H. Dapito · Columbia University3 papers (2012–2020)Ze Zheng · Columbia University3 papers (2016–2020)Luca Valenti · Memorial Hospital3 papers (2018–2020)Ajay Nair · Columbia University3 papers (2021–2022)Aashreya Ravichandra · Columbia University2 papers (2021–2022)Adebowale Adeyemi · Columbia University2 papers (2012–2016) · 2 papers (2021–2022)Carla V. Rothlin · Yale University2 papers (2019–2022)